| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT06795126 Little NIRVANA for Pediatric Pain and Anxiety |
date change Primary completion pushed: 2026-04-30 -> 2026-11-30 |
| 2026-08-12 | NCT06795126 Little NIRVANA for Pediatric Pain and Anxiety |
date change Completion pushed: 2026-08-31 -> 2027-08-31 |
| 2026-08-02 | NCT06264700 Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness |
overall status: Recruiting → Unknown |
| 2026-08-01 | NCT05645224 VR-PAT for Pain and Anxiety Management During Pediatric Dermatologic Laser Procedures |
date change Completion pushed: 2026-06-30 -> 2026-12-31 |
| 2026-08-01 | NCT07206849 Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) |
date change Primary completion pushed: 2030-05 -> 2030-11 |
| 2026-08-01 | NCT07206849 Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) |
date change Completion pushed: 2037-05 -> 2037-11 |
| 2026-07-30 | NCT03520751 Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A |
critical Withdrawn before enrolling |
| 2026-07-30 | NCT03520751 Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A |
critical Trial withdrawn: Study is withdrawing to the retirement of the PI. |
| 2026-07-30 | NCT03520751 Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A |
Enrollment reduced: 3 -> 0 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-21 | NCT07718204 The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow… | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07291102 | Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk… | Medulloblastoma | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT05267821 | Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS | Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) | Recruiting |
| Phase 2 | |||
| NCT04467671 | Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered… | HLH - Hypoplastic Left Heart Syndrome | Recruiting |
| NCT05135975 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in… | Neuroblastoma | Recruiting |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Adamantinous Craniopharyngioma | Recruiting |
| NCT05233397 | ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Adamantinomatous Craniopharyngioma | Recruiting |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and… | High Grade Glioma | Recruiting |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG… | High Grade Glioma | Recruiting |
| NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High… | Diffuse Intrinsic Pontine Gliomas (DIPG) | Recruiting |
| NCT02378428 | MIBG Therapy for Patients With MIBG Avid Tumors | MIBG Avid Tumors | Active, Not Recruiting |
| NCT07644312 | Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG | High Grade Glioma | Not Yet Recruiting |
| NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | High Grade Glioma (HGG) of the Brain With BRAF Aberration | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT05503134 | Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for… | Acute Myeloid Leukemia | Recruiting |
| NCT04211675 | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | Relapsed Neuroblastoma | Recruiting |
| NCT04722029 | Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory… | Adenovirus Infection | Recruiting |
| NCT05634369 | A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell… | Pediatric Sarcoma, Refractory | Recruiting |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | High Grade Glioma | Recruiting |
| NCT07026942 | Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML | Relapsed/Refractory AML | Not Yet Recruiting |
| NCT03431090 | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic… | Myelodysplasia | Active, Not Recruiting |
| Phase 1 | |||
| NCT04254419 | Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells | High Grade Glioma | Recruiting |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine… | High Grade Glioma | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | High Grade Glioma | Recruiting |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | High Grade Glioma | Recruiting |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for… | Acute Lymphoblastic Leukemia, in Relapse | Not Yet Recruiting |
| Not specified | |||
| NCT05547165 | Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight… | Ductus Arteriosus, Patent | Recruiting |